title: A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer.
abstract: The identification of oncogenic driver mutations in non-small cell lung cancer (NSCLC) has led to a paradigm shift and the development of specific molecular treatments. Tumors harboring a rearranged EML4-ALK fusion oncogene are highly sensitive to therapy with ALK-targeted inhibitors. Crizotinib is the first approved treatment for advanced lung tumors containing this genetic abnormality. In this mini review, we discuss the existing data on crizotinib as well as ongoing trials involving this medication. A brief overview of the known resistance mechanisms to crizotinib will also be presented followed by a summary of the ongoing trials involving next-generation ALK-inhibitors or other targeted therapies in patients with ALK+ NSCLC.
authors.affiliation: Department of Oncology, Segal Cancer Center, Sir Mortimer B. Davis Jewish General Hospital , Montreal, QC , Canada.
authors.forename: Khashayar
authors.initials: K
authors.lastname: Esfahani
authors.affiliation: Division of Pulmonary Diseases, Department of Oncology, Peter Brojde Cancer Center , Montreal, QC , Canada.
authors.forename: Jason Scott
authors.initials: JS
authors.lastname: Agulnik
authors.affiliation: Department of Oncology, Segal Cancer Center, Sir Mortimer B. Davis Jewish General Hospital , Montreal, QC , Canada.
authors.forename: Victor
authors.initials: V
authors.lastname: Cohen
keywords: ALK-inhibitors; anaplastic lymphoma kinase; clinical trials as topic; crizotinib; driver mutations; non-small cell lung cancer
references.citation: Clin Cancer Res. 2012 Nov 15;18(22):6219-26
references.pmid: 22843788
references.citation: Sci Transl Med. 2012 Feb 8;4(120):120ps2
references.pmid: 22323827
references.citation: Cancer Res. 2010 Dec 1;70(23):9827-36
references.pmid: 20952506
references.citation: Clin Cancer Res. 2012 Sep 1;18(17):4682-90
references.pmid: 22912387
references.citation: N Engl J Med. 2013 Jun 20;368(25):2395-401
references.pmid: 23724914
references.citation: Cancer Res. 2011 Sep 15;71(18):6051-60
references.pmid: 21791641
references.citation: Curr Opin Oncol. 2014 Mar;26(2):159-64
references.pmid: 24463348
references.citation: Lancet Oncol. 2013 Jun;14(7):590-8
references.pmid: 23639470
references.citation: Clin Cancer Res. 2009 May 1;15(9):3143-9
references.pmid: 19383809
references.citation: Genomics. 2013 Sep;102(3):157-62
references.pmid: 23434628
references.citation: N Engl J Med. 2014 Mar 27;370(13):1189-97
references.pmid: 24670165
references.citation: Cancer Discov. 2013 Apr;3(4):430-43
references.pmid: 23533265
references.citation: Lung Cancer. 2014 May;84(2):110-5
references.pmid: 24598368
references.citation: Nat Med. 2013 Nov;19(11):1389-400
references.pmid: 24202392
references.citation: J Clin Oncol. 2013 Nov 1;31(31):3987-96
references.pmid: 24101047
references.citation: Chem Biol Drug Des. 2011 Dec;78(6):999-1005
references.pmid: 22034911
references.citation: J Thorac Oncol. 2013 May;8(5):574-81
references.pmid: 23449277
references.citation: Cancer Res. 2011 Jul 15;71(14):4920-31
references.pmid: 21613408
references.citation: Clin Cancer Res. 2012 Mar 1;18(5):1472-82
references.pmid: 22235099
references.citation: J Thorac Oncol. 2013 Sep;8(9):e85-6
references.pmid: 23945393
references.citation: BMC Res Notes. 2013 Nov 26;6:489
references.pmid: 24279718
references.citation: N Engl J Med. 2010 Oct 28;363(18):1734-9
references.pmid: 20979473
references.citation: Lung Cancer. 2014 Jan;83(1):37-43
references.pmid: 24199682
references.citation: Clin Cancer Res. 2013 Jun 1;19(11):3068-77
references.pmid: 23553849
references.citation: J Thorac Oncol. 2013 Apr;8(4):e32-3
references.pmid: 23486271
references.citation: BMC Cancer. 2013 Oct 10;13:471
references.pmid: 24112608
references.citation: J Clin Oncol. 2011 May 20;29(15):e443-5
references.pmid: 21422405
references.citation: J Clin Oncol. 2010 Nov 20;28(33):4953-60
references.pmid: 20940188
references.citation: Cancer Cell. 2011 May 17;19(5):679-90
references.pmid: 21575866
references.citation: Clin Cancer Res. 2011 Dec 1;17(23):7394-401
references.pmid: 21948233
references.citation: Clin Cancer Res. 2013 Aug 1;19(15):4273-81
references.pmid: 23729361
references.citation: Drugs. 2013 Dec;73(18):2031-51
references.pmid: 24288180
references.citation: N Engl J Med. 2013 Jun 20;368(25):2385-94
references.pmid: 23724913
references.citation: Nature. 2007 Aug 2;448(7153):561-6
references.pmid: 17625570
references.citation: Cancer Res. 2010 Dec 15;70(24):10038-43
references.pmid: 21030459
references.citation: J Thorac Oncol. 2013 Apr;8(4):415-22
references.pmid: 23344087
references.citation: Front Oncol. 2012 May 11;2:41
references.pmid: 22649787
references.citation: Cancer Biol Ther. 2014 May;15(5):570-7
references.pmid: 24556908
references.citation: Bioorg Med Chem. 2012 Feb 1;20(3):1271-80
references.pmid: 22225917
references.citation: Sci Transl Med. 2012 Feb 8;4(120):120ra17
references.pmid: 22277784
references.citation: N Engl J Med. 2010 Oct 28;363(18):1693-703
references.pmid: 20979469